The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
First data with the biotech’s new EGFR project prompts a 236% share price bump.
The company puts its faith in a new lymphodepletion regimen to overcome mediocre early results with its lead Car-NK therapy.
Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.
Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.
Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.
After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.